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Abstract
Background—Single nucleotide polymorphisms (SNPs) in pathways influencing lymph node 
(LN) metastasis and estrogen receptor (ER) status in breast cancer may partially explain inter-
patient variability in prognosis. We examined 154 SNPs in 12 metastasis-related genes for 
associations with breast cancer risk, stratified by LN and ER status, in European-American (EA) 
and African-American (AA) women.
Methods—2,671 women enrolled in the Women’s Circle of Health Study were genotyped. 
Pathway analyses were conducted using the adaptive rank truncated product (ARTP) method, with 
pARTP≤0.10 as significant. Multi-allelic risk scores were created for the ARTP-significant gene(s). 
Single-SNP and risk score associations were modeled using logistic regression, with false 
discovery rate (FDR) p-value adjustment.
Results—Although single-SNP associations were not significant at pFDR<0.05, several genes 
were significant in the ARTP analyses. In AA women, significant ARTP gene-level associations 
included CDH1 with LN+ (pARTP=0.10; multi-allelic OR=1.13, 95% CI 1.07–1.19, pFDR=0.0003) 
and SIPA1 with ER− breast cancer (pARTP=0.10; multi-allelic OR=1.16, 95% CI 1.02–1.31, 
pFDR=0.03). In EA women, MTA2 was associated with overall breast cancer risk (pARTP=0.004), 
regardless of ER status, and with LN− disease (pARTP=0.01). Also significant were SATB1 in ER− 
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(pARTP=0.03; multi-allelic OR=1.12, 95% CI 1.05–1.20, pFDR=0.003) and KISS1 in LN− 
(pARTP=0.10; multi-allelic OR=1.18, 95% CI 1.08–1.29, pFDR=0.002) analyses. Among LN+ 
cases, significant ARTP associations were observed for SNAI1, CD82, NME1, and CTNNB1 
(multi-allelic OR=1.09, 95% CI 1.04–1.14, pFDR=0.001).
Conclusion—Our findings suggest that variants in several metastasis genes may affect breast 
cancer risk by LN or ER status, although verification in larger studies is required.
Keywords
Breast neoplasms; Single nucleotide polymorphism; Lymph nodes; Estrogen receptor; African-
American
1. Introduction
Breast cancer prognosis is excellent when diagnosed and treated at an early stage, but is 
poorer when metastatic disease is present. The presence of axillary lymph node (LN) 
metastases at diagnosis is a strong risk factor for future recurrence and poorer prognosis. 
Once metastasized to distant sites, breast cancer is generally considered incurable and the 
majority of breast cancer-associated mortality results from metastatic disease [1]. Breast 
cancer mortality rates are higher among African-American (AA) women compared to 
European-American (EA) women, for reasons that are not fully understood. AA women tend 
to present with breast cancer at a younger age, with more aggressive tumor characteristics 
and a greater likelihood of disease progression and recurrence [2,3]. It is therefore critical to 
identify mechanisms of metastasis, particularly those that may differentially affect AA and 
EA patients.
Inherited genetic variation in metastasis-associated genes might partially explain inter-
patient variability in successful metastatic dissemination and colonization [4]. A great 
number of metastasis-associated genes have been identified, including those involved in 
epithelial-mesenchymal transition (EMT), metastasis suppressor genes, and others [5].
EMT has been hypothesized as a mechanism by which tumor cells acquire metastatic 
potential, and genes involved in this process include E-cadherin (CDH1), Snail (SNAI1), and 
β-catenin (CTNNB1) [6]. SATB homeobox 1 (SATB1) is a genome organizing protein, 
which has been shown to affect expression of many genes involved in metastasis, including 
EMT-related genes [7]. Metastasis suppressor genes are those that can inhibit metastatic 
formation without affecting primary tumor growth, and include BRMS1, CDH1, CD82/
KAI1, KISS1, and NME1 [8]. These genes belong to diverse pathways, including gene 
transcription, cell adhesion, extracellular matrix remodeling, and apoptosis. Metastasis-
associated 1 family members (MTA1, MTA2, and MTA3) are part of estrogen receptor (ER) 
signaling pathways and also interact with the EMT-related genes SNAI1 and CDH1 [9]. 
Finally, the metastasis efficiency modifying gene SIPA1 alters cell adhesion [10] and 
promotes metastasis in vivo [11].
The purpose of this study was to examine common genetic variants in metastasis-related 
genes for associations with breast cancer risk, stratified by ER and LN status, and likelihood 
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of ER− and LN+ tumors in both EA and AA women, using a combination of single-SNP and 
gene-based analyses. We selected 12 metastasis-associated genes (BRMS1, CDH1, CD82/
KAI1, CTNNB1, KISS1, MTA1, MTA2, MTA3, NME1, SATB1, SIPA1, and SNAI1) for 
analysis, focusing on those with few or no previously published studies in breast cancer.
2. Materials and Methods
2.1. Study population
The Women’s Circle of Health Study (WCHS) is an ongoing case-control study designed to 
examine the role of genetic and non-genetic factors in relation to risk of breast cancer in AA 
and EA women. The study design, enrollment criteria, and collection of biospecimens and 
questionnaire data have previously been described in detail [12,13]. Eligible cases were 
women who self-identified as AA or EA, were 20–75 years of age at diagnosis, had no 
previous history of cancer other than non-melanoma skin cancer, were diagnosed with 
primary, incident, histologically confirmed invasive breast cancer or ductal carcinoma in situ 
(DCIS), and were English speaking. In New York City, cases were identified through 
collaborating hospitals in Manhattan, Brooklyn, Bronx, and Queens, and in New Jersey, 
rapid case ascertainment using the State Cancer Registry was conducted. Controls were 
identified contemporaneously using random digit dialing and had the same inclusion criteria 
as cases, but with no history of any cancer diagnosis other than non-melanoma skin cancer. 
Controls were frequency matched to cases by self-reported race, 5-year age categories, and 
telephone exchange (New York City) or county of residence (New Jersey). In New Jersey, 
AA controls were also invited to participate through community recruitment events [14]. 
Following agreement to participate, in-person interviews were conducted to complete 
informed consent and an extensive epidemiologic questionnaire. Blood and/or saliva samples 
were collected for later extraction of DNA. Tumor characteristics were abstracted from 
pathology reports.
This study was approved by the Institutional Review Boards at Roswell Park Cancer 
Institute (RPCI), the Rutgers Cancer Institute of New Jersey (CINJ), the Icahn School of 
Medicine at Mount Sinai, and the participating hospitals in New York City.
2.2. DNA sample preparation
Blood and saliva were collected as sources of genomic DNA, which was isolated from blood 
using FlexiGene™ DNA isolation kits (Qiagen Inc., Valencia, CA) and from Oragene™ 
(DNA Genotek Inc., Kanata, Ontario, Canada) saliva sample collection kits, according to the 
respective manufacturer’s protocols. Genomic DNA was evaluated and quantitated by 
Nanodrop UV-spectrometer (Thermo Fisher Scientific Inc., Wilmington, DE) and 
PicoGreen-based fluorometric assay (Molecular Probes, Invitrogen Inc., Carlsbad, CA), and 
stored at −80°C until analysis.
2.3. SNP selection
SNPs for the studied genes were chosen using the SNPInfo candidate gene SNP selection 
pipeline (National Institutes of Environmental Health Sciences (http://
snpinfo.niehs.nih.gov/)) [15], which selects multi-population tag SNPs based on HapMap 
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genotype and linkage disequilibrium (LD) data. For each gene, SNPs were identified for the 
CEU (Utah residents with Northern and Western European ancestry) and YRI (Yoruba in 
Ibadan, Nigeria) populations using the following settings: 5kb upstream and downstream 
flanking regions, 0.8 tagging proportion cutoff, 0.05 minor allele frequency (MAF) cutoff, 
0.8 LD threshold, minimum of two SNPs tagged by a given tag SNP, and minimum of one 
tag SNP tagged per gene. In addition to the tagging SNPs, we also identified several 
validated SNPs using the National Center for Biotechnology Information dbSNP database 
(http://www.ncbi.nlm.nih.gov/snp/) that had MAF >0.05 in the CEU and/or YRI populations 
and were either located in coding or near gene/untranslated regions or had been previously 
studied (rs1052566, rs3116068 (BRMS1); rs2306364, rs3741378, rs75894763 (SIPA1)). A 
total of 154 tag and candidate SNPs were ultimately selected for genotyping (Supplementary 
Table 1).
2.4. Genotyping and quality control
Genotype and quality control/assurance methods have been described in detail previously 
[13]. Genotyping was conducted on all participants who were enrolled in the study through 
June 2011 and had sufficient DNA available for analysis. SNPs were genotyped using the 
Illumina GoldenGate assay (Illumina Inc., San Diego, CA), with five percent duplicates and 
two sets of in-house trio samples included for quality control purposes. The concordance 
among blind duplicate pairs was >99.9%. The average successful genotyping rate for each 
sample and each SNP was >95%. As shown in Supplementary Table 1, 22 SNPs were 
excluded from further analyses because they were monomorphic (n=1), violated Hardy-
Weinberg equilibrium (p<0.00001; n=8), or had low call rate (<98%) in EA and/or AA 
controls (n=9), or had MAF <5% in both EA and AA controls (n=4), leaving 132 SNPs for 
analysis.
2.5. Genetic ancestry estimate
A previously validated panel of 100 ancestry informative markers (AIMs) was also 
genotyped to ascertain genetic ancestry and control for population admixture [16]. Ninety-
five AIMs were successfully genotyped and, based on this genotype data, estimates of 
European and African ancestry were obtained using the STRUCTURE program [17]. We 
excluded 41 women with self-reported race as “other” and 12 women with ≥85% estimated 
ancestry discordant with their self-reported race (n=11 in AAs and n=1 in EAs). Proportion 
of EA genetic ancestry was included as a continuous covariate in statistical analyses.
2.6. Statistical analysis
The final dataset included 2,671 women: 658 EA cases, 649 EA controls, 621 AA cases, and 
743 AA controls. ER and LN status was available for 943 and 975 cases, respectively. All 
analyses were conducted for EA and AA participants separately. Demographic variables and 
tumor characteristics were compared between groups using Chi-squared, Fisher’s exact, or t-
tests, as appropriate. Genotype and allele frequencies were compared between EA and AA 
controls using Chi-squared tests, and a Bonferroni correction was applied to adjust for 
multiple comparisons.
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Unconditional logistic regression was used to estimate odds ratios (OR) and 95% confidence 
intervals (CI) for 132 SNPs in association with the study outcomes (risk of breast cancer in 
all cases, risk of breast cancer limited to invasive cases, risk of breast cancer stratified by LN 
and ER status, and case-case comparisons of LN and ER status). For each SNP, codominant, 
dominant, recessive, and additive genetic models were tested, using the homozygous 
common genotype in the EA group as the reference category. Age and proportion of EA 
genetic ancestry were chosen a priori as covariates for single-SNP analyses. All analyses 
were performed separately in AA and EA women, using the same genotype as reference 
category to facilitate comparisons between the two groups. False discovery rate testing was 
implemented to control for multiple comparisons [18]. Chi-squared and t-tests, logistic 
regression, and false discovery rate analyses were performed using SAS version 9.3.
To consider all markers jointly, pathway analyses were conducted using the adaptive rank 
truncated product method (ARTP). The ARTP method is a gene-based approach to pathway 
analysis that can confer a statistical power advantage in situations in which the causal variant 
is located in genes with fewer SNPs within a pathway, because it limits the effect of many 
SNPs in the larger gene(s) with null associations [19]. SNPs with MAF <0.05 in either EA 
(n=22) or AA (n=1) control groups were excluded from ARTP analysis in that group, 
leaving a total of 110 and 131 SNPs available for analysis in EA and AA participants, 
respectively. LD statistics generated for all SNP pairs in EA and AA controls were used to 
further filter SNPs in strong LD, defined as r2 >0.80 between any two markers. For each pair 
or group of SNPs in strong LD, the SNP with the strongest single-SNP association was 
retained. This resulted in a final set of 87 independent SNPs for EA participants and 122 
independent SNPs for AA participants. For power considerations, SNPs with variant 
homozygous genotype frequencies ≤10% were collapsed to combine the heterozygous and 
variant homozygous genotype categories.
The ARTP method relies on user-defined pathways. To identify interaction networks 
between the 12 genes we selected for genotyping, we employed the GeneMANIA gene 
interaction prediction server (www.genemania.org) [20], using the default weighting 
method. We considered those genes that interacted with each other to form a pathway. The 
ARTP method was then used to obtain gene and pathway p-values for associations with each 
outcome. Permutation p-values were obtained by permuting the outcome vector (i.e., case-
control status, ER status, or LN status, as appropriate) 10,000 times, while adjusting for age 
and proportion of European ancestry, using the default truncation points. Since permutation 
testing is a very conservative method for controlling the family-wise Type I error rate, we 
chose the more liberal p ≤0.10 as the gene and/or pathway significance threshold. Analyses 
were performed using the R package “ARTP”, version 2.0.4 (R Foundation for Statistical 
Computing, Vienna, Austria).
The ARTP method provides an overall test of whether variants in each gene or pathway are 
associated with risk, but it does not provide an estimate of the magnitude or direction of the 
association. Therefore, multi-allelic risk scores were constructed to estimate the risk of 
breast cancer associated with genes found to be significant in ARTP analyses [21]. For each 
outcome in which one or more genes were significant at pARTP≤0.10, SNPs in these 
significant genes were included if the additive single-SNP model OR was <0.95 or >1.05. If 
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the additive model OR for a given SNP was between 0.95–1.05, the association was 
considered null and the SNP was excluded from the summary score. For each SNP, the 
direction of the association with its respective outcome (positive or inverse) was determined 
using the additive single-SNP model. SNPs with positive associations were assigned 0, 1, 
and 2 at-risk alleles, and SNPs with inverse associations were assigned 2, 1, and 0 at-risk 
alleles. For each outcome, the summary score SNPs were added together; participants 
missing genotype for one or more SNPs were not assigned a summary score, to avoid 
misclassification with respect to number of at-risk alleles.
Summary scores were included as continuous variables in logistic regression models. Age 
and proportion of European ancestry were included as covariates in minimally adjusted 
models. Participant and tumor characteristics that were significant at p<0.05 in EA or AA 
comparisons were included as additional covariates in fully adjusted models. P-values 
derived from the logistic regression models were adjusted for multiple comparisons using 
the FDR method.
3. Results
Selected participant characteristics are shown in Table 1. When the case group was restricted 
to those with invasive tumors, the distribution of characteristics between cases and controls 
was similar among both EA and AA participants (data not shown). When compared by ER 
and LN status, characteristics were generally similar for both EA and AA cases. LN− cases 
tended to be older than LN+ cases in both ancestral groups. Among AA cases, women who 
were LN+ were significantly more likely to be premenopausal than those who were LN− 
(data not shown).
Genotype and allele frequencies were compared between EA and AA controls and results 
are shown in Supplementary Table 2. For most of the SNPs we measured, genotype and 
allele frequencies were significantly different between the groups, after Bonferroni 
correction for multiple comparisons.
Results of single-SNP analyses, under the additive and dominant models, for comparisons 
by ER status and LN status are shown in Supplementary Tables 3 and 4, respectively. After 
FDR adjustment, none of the associations remained significant.
Using GeneMANIA, we found that, by including the ESR1 (ERα) gene, all of the 
metastasis-associated genes selected for this study could be linked, as shown in 
Supplementary Figure 1. We therefore considered the 12 genes included in this study to be 
components of a “metastasis pathway” for ARTP analysis. The log10-transformed gene and 
pathway p-values for each outcome are shown in Figure 1; the raw p-values are provided in 
Supplementary Table 5.
3.1. ARTP results in EA women
In EA women (Figure 1A), the overall pathway was significant only when all cases and 
controls were compared (pARTP=0.10). In the analysis of all cases vs. controls and when 
restricted to cases with invasive tumors vs. controls, the MTA2 gene was highly significant 
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(pARTP=0.004 and pARTP=0.01, respectively). Risk of LN+ disease was significantly 
associated with SNAI1 (pARTP=0.10), CD82 (pARTP=0.05), NME1 (pARTP=0.10), and 
CTNNB1 (pARTP=0.09). When LN− cases were compared to controls, the KISS1 
(pARTP=0.10) and MTA2 (pARTP=0.01) genes were significant. In case-case analysis, 
positive LN status was significantly associated with the SNAI1 (pARTP=0.01) and CTNNB1 
(pARTP=0.06) genes. When stratified by ER status, the MTA2 gene (pARTP=0.02) was 
significantly associated with risk of ER+ breast cancer, while the MTA2 (pARTP=0.08) and 
SATB1 (pARTP=0.03) genes were significantly associated with risk of ER− breast cancer. 
None of the genes were significant in case-case analysis.
3.2. ARTP results in AA women
In AA women (Figure 1B), fewer significant associations were observed. Risk of LN+ breast 
cancer was significantly associated with the CDH1 gene (pARTP=0.10). In case-case 
analysis, SIPA1 was significantly associated with negative ER status (pARTP=0.09) and when 
compared to controls (pARTP=0.10). None of the overall pathways were significant, nor were 
genes in any of the other outcomes.
3.3. Multi-allelic risk score results in EA women
In EA women, risk scores made from two SNPs in MTA2 were associated with increased 
risk of breast cancer among all cases and when limited to invasive breast cancer in fully 
adjusted models (Table 2; all cases vs. controls OR=1.15, 95% CI 1.04–1.26, pFDR=0.01; 
invasive cases vs. controls OR=1.19, 95% CI 1.07–1.33, pFDR=0.003). When combined, 
twenty-seven SNPs in the SNAI1, CD82, NME1, and CTNNB1 genes were significantly 
associated with risk of LN+ breast cancer (OR=1.09, 95% CI 1.04–1.14, pFDR=0.001). 
Similar findings were observed for the comparison of LN− cases to controls, using a risk 
score composed of five SNPs in the MTA2 and KISS1 genes (OR=1.18, 95% CI 1.08–1.29, 
pFDR=0.002). Two SNPs in MTA2 and 13 SNPs in MTA2 and SATB1 were used to 
construct risk scores for ER+ and ER− cases, respectively, compared to controls. The 
MTA2-score was significantly associated with risk of ER+ breast cancer (OR=1.16, 95% CI 
1.05–1.30, pFDR=0.01), and the MTA2/SATB1-score with ER− disease (OR=1.12, 95% CI 
1.05–1.20, pFDR=0.003). In case-case analysis, the risk score comprised of six SNPs in 
SNAI1 and CTNNB1 was significantly associated with positive LN status, even when 
adjusting for HER2 status, tumor grade, and tumor size (OR=1.15, 95% CI 1.01–1.31, 
pFDR=0.04).
3.4. Multi-allelic risk score results in AA women
In AA women, the multi-allelic risk score composed of 19 SNPs in the CDH1 gene was 
significantly associated with increased risk of LN+ breast cancer (Table 2; OR=1.13, 95% 
CI 1.07–1.19, pFDR=0.0003). Five SNPs in SIPA1 were used to make risk scores for 
analyses of ER status in case-control and case-case analyses. When compared to controls, 
the SIPA1 risk score was significantly associated with increased risk of ER− breast cancer 
(OR=1.16, 95% CI 1.02–1.31, pFDR=0.03). In case-case analysis, however, the association 
was not significant when adjusted for PR status, tumor grade, tumor size, and stage.
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4. Discussion
In this study, although no single-SNP association remained significant after correction for 
multiple comparisons, the gene-based ARTP analyses, which are implicitly controlled for 
multiple comparisons via permutation testing, revealed several significant gene-level 
associations in EA (MTA2 with overall, ER+, ER−, and LN− breast cancer; SATB1 with ER
− breast cancer; KISS1 with LN− breast cancer; and SNAI1, CTNNB1, CD82, and NME1 
with LN+ breast cancer) and AA (CDH1 with LN+ breast cancer; SIPA1 with ER− breast 
cancer) participants.
MTA2 has histone deacetylase activity and is a subunit of Mi-2/NuRD chromatin 
remodeling complexes [22]. By interacting with Twist1, a transcription factor that is a 
master regulator of EMT, MTA2 mediates repression of E-cadherin [23]. Furthermore, by 
binding to ERα and acting as a repressor, MTA2 modulates acetylation and transcriptional 
activity of ERα [24]. One of the two SNPs included in the gene-based analysis, rs11231156, 
is predicted by RegulomeDB [25] to be likely to affect transcription binding and is linked to 
expression of a gene target (RegulomeDB score 1f).
SATB1 is a nuclear matrix and scaffold attachment region binding protein [26] that acts as a 
genome organizer [27]. Gene expression profiling of the metastatic breast cancer cell line 
MDA-MB-231 has shown that, among others, SATB1 downregulates CTNNB1, CDH1, 
BRMS1, CD82, KISS1, and NME1 [7]. One study examining SNPs in SATB1 with respect 
to breast cancer found that homozygous carriers of the −3600T/−3363A/−2984C haplotype 
had improved overall survival [28]. We genotyped rs1475469, which is in strong LD with 
−2984C>T (rs6762753; r2=0.96; CEU population, 1000 Genomes Phase 3 data). 
Furthermore, using the GRASP (Genome-wide Repository of Associations between SNPs 
and Phenotypes) database [29], we found that two SNPs included in the gene-based analysis, 
rs4129096 and rs9714119, were associated with breast cancer mortality at p=0.01 and 
p=0.0006, respectively [30].
The transcription factor SNAI1 is a key developmental EMT regulator and transcriptional 
repressor of E-cadherin and ERα [31–33]. Two of the variants in the gene-based analysis, 
rs6020177 and rs6091080, are predicted by RegulomeDB to affect binding (scores of 1f and 
2b, respectively). While the role of SNAI1 variants in LN metastasis has not previously been 
examined, the variant allele of the nonsynonymous SNP rs4647958 has been associated with 
reduced overall risk of breast cancer among women with older age at first pregnancy [34].
The transcriptional co-factor and structural protein β-catenin (CTNNB1) links E-cadherin 
(CDH1) to the actin cytoskeleton and is the central protein of the Wnt signaling pathway, 
which regulates cell proliferation, differentiation, and apoptosis [35]. Two variants 
(rs4135385 and rs1307263) have previously been examined using a candidate gene 
approach, although not in EA or AA populations, with conflicting results as to breast cancer 
risk [36,37].
CD82, NME1, and KISS1 are metastasis suppressor genes, which inhibit metastatic 
formation without affecting primary tumor growth. CD82/KAI1 is a cell surface 
glycoprotein that interacts with the Duffy antigen chemokine receptor, an endothelial cell 
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surface protein, to anchor tumor cells to vascular endothelial cells, inducing tumor cell 
senescence and suppressing metastatic spread [38].
NME1 (also known as NM23-H1) is regulated by p53 and estrogen [39,40], and affects 
expression of genes involved in cell migration, apoptosis, and angiogenesis through its 
interaction with ERα [41]. Two promoter region SNPs (rs2302254 and rs16949649), both 
included in our analysis, have been implicated in an increased risk of relapse, metastasis, 
and breast cancer-specific mortality [42] and are predicted by RegulomeDB to be likely to 
affect binding (scores of 2b and 1f, respectively).
KISS1 appears to be involved in the NF-κB and ER signaling pathways. Induction of KISS1 
expression resulted in decreased expression of Snail2, a transcription factor involved in 
EMT, and an increase in E-cadherin expression [43], indicating that one metastasis 
suppressive function of KISS1 is to inhibit EMT and maintain the epithelial phenotype. One 
SNP we examined, rs3795573, was predicted to affect binding (RegulomeDB score 2b). One 
prior study found that rs5780218 was significantly associated with risk of breast cancer 
among Mexican patients [44], but this SNP is not in LD with any of the ones we included.
CDH1 is a tumor suppressor and metastasis suppressor, the loss of which promotes tumor 
cell invasiveness and induces EMT in experimental models. E-cadherin (CDH1) is a 
calcium-dependent cell-cell adhesion protein that is crucial for maintaining cell polarity, 
epithelial architecture and structural integrity, and preserving cell-cell interactions [35]. 
Several studies have examined polymorphisms in CDH1 in relation to breast cancer risk or 
prognosis, with conflicting results [34,45–50], although few data exist for AA populations. 
Four of the SNPs included in the gene-based analysis are predicted to affect binding by 
RegulomeDB (rs7188750, 1b; rs9941051, 1f; rs10431923, 1f; rs9940250, 2b).
SIPA1 catalyzes the hydrolysis of guanosine triphosphate to guanosine diphosphate and has 
been shown to regulate cell adhesion [10]. Several SIPA1 variants have been studied, mainly 
in white populations, but associations with breast cancer risk and survival have not been 
consistent [51,52]. In one study, rs931127 (promoter region) and rs746429, a synonymous 
SNP (Ala920Ala), were associated with increased likelihood of having nodal metastases at 
diagnosis, while a nonsynonymous SNP, rs3741378 (Ser182Phe), was associated with ER 
and PR negative tumors [53]. We previously observed an increased likelihood of the HER2-
expressing subtype, which includes ER− tumors, in women with the variant rs3741378 
genotype, although the estimate was imprecise due to small numbers [54]. Here, we found 
that SIPA1 variants, including rs3741378, were associated with ER− breast cancer, in case-
control and case-case analyses, in AA women.
Strengths of this study include the use of in-person interviews to gather detailed information 
on family history and hormone-related variables, which permitted greater control of 
potential confounding variables. In addition, this study used a panel of 100 AIMs to address 
population stratification within categorical racial groups, a well-known source of 
confounding due to admixture in genetic epidemiology studies. AIMs allow for estimation 
of individual ancestral proportions, which can then be included as a covariate in multivariate 
models. African populations are known to be more genetically diverse than non-African 
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populations [55]. Admixture with individuals of European ancestry has further contributed 
to genetic diversity in AAs. The panel we selected has been shown to reliably estimate the 
proportion of European ancestry in AA individuals, using data from the Black Women’s 
Health Study [16]. Since these AIMs were designed to capture admixture in AAs, it is 
unclear how well they capture admixture in EAs; however, since there is less admixture in 
EA groups, confounding is less likely to have affected our results.
Our study is limited, however, by the inclusion of only 12 genes; it is likely that other 
metastasis-related genes contribute to breast cancer development, particularly LN+ tumors, 
perhaps by interacting with the genes we have investigated here. We examined common 
variants by identifying a set of tag SNPs within each gene, but there may be other important 
genetic contributions that we were unable to examine because of sample size limitations, 
such as rare variation and gene-environment interactions. We also restricted our definition of 
gene region to +/− 5kb upstream and downstream. However, since SNPs that affect gene 
expression may be found at distances further than this, it is possible that SNPs with 
important functional effects were missed by our definition.
We did not have recurrence or survival data available to examine long-term outcomes, which 
may be important for understanding the effects of these variants on metastasis, and our 
sample size precluded stratification by tumor subtype. Furthermore, we were unable to 
compare early-stage and metastatic breast cancer cases, due to sample size limitations; our 
study contained only one EA and four AA stage IV cases. Instead, we examined associations 
with LN status, a strong prognostic variable, and ER status, since ER− tumors are typically 
more aggressive and have a worse prognosis. Although ER status and LN status were 
missing for 26% and 12% of all cases and invasive tumor cases, respectively, participant 
characteristics were generally similar between those with and without known ER and LN 
status, indicating that our estimates were unlikely to be biased by missingness for these 
features.
Our study is also limited by the lack of validation using an independent population, as well 
as the fact that the sample sizes within subgroups prohibit separation into testing and 
training sets for cross-validation strategies. Finally, given the small numbers of participants 
in our subgroup analyses, our study may be underpowered to detect small effect sizes for the 
genes we examined. We therefore cannot rule out the possibility of false negative findings. 
For these reasons, additional large, well-powered studies with long-term outcome data are 
needed both to replicate the findings we report herein as well as further investigate the 
contribution of genetic variation to metastasis.
In conclusion, we found evidence suggesting that variants in different metastasis-related 
genes may affect risk of breast cancer, by LN and ER status, in EA and AA women. Several 
promising associations were identified that require confirmation and, in particular, 
investigation of SNP effects on recurrence and survival. Additional studies are needed to 
better understand the genetic basis for the development of breast cancer in different ancestral 
groups, particularly as it relates to aggressive tumor subtypes and metastatic potential.
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ARTP Adaptive rank truncated product
BRMS1 Breast cancer metastasis suppressor 1
CD82 CD82 molecule
CDH1 Cadherin 1, type 1, E-cadherin
CEU Utah residents with Northern and Western European ancestry
CI Confidence interval
CINJ Cancer Institute of New Jersey
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EA European-American
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KISS1 KiSS-1 metastasis suppressor
LD Linkage disequilibrium
LN lymph node
MAF Minor allele frequency
MTA1 Metastasis-associated 1
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MTA3 Metastasis-associated 1 family, member 3
NME1 NME/NM23 nucleoside diphosphate kinase 1
OR Odds ratio
PR Progesterone receptor
RPCI Roswell Park Cancer Institute
SATB1 Special AT-rich binding protein homeobox 1
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Figure 1. Adaptive rank truncated product method p-values
A. European-American women.
B. African-American women.
Pathway and gene-level permutation p-values were obtained by permuting the response 
vector 10,000 times for each outcome, using default truncation points. Permutation p-values 
are shown on the log scale; −log(p)≥1.0 (equivalent to p≤0.10) was considered significant.
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